Articles tagged "Kidney transplantation"

2021 American Transplant Congress
Non-Invasive Measurement of Transplant Kidney Fibrosis Using Photoacoustic Imaging
E. Hysi¹, X. He¹, A. Krizova¹, M. Ordon¹, K. T. Pace¹, M. Farcas¹, M. C. Kolios², D. A. Yuen¹
¹St. Michael's Hospital, Toronto, ON, Canada, ²Ryerson University, Toronto, ON, Canada
*Purpose: The presence of donor kidney fibrosis adversely impacts transplant outcome. Biopsy remains the only method that can assess fibrosis, despite being subjected to sampling…
2021 American Transplant Congress
Reassessing TCMR in Kidney Transplant Indication Biopsies: Emerging Evidence for Partial Exhaustion in Late TCMR
P. Halloran¹, J. Reeve¹, &. the INTERCOMEX Study Group²
¹Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada, ²., ., AB, Canada
*Purpose: We rederived the MMDx rejection archetypes in an expanded set of 1679 kidney transplant biopsies to add power and potentially define heterogeneity in TCMR.…
2021 American Transplant Congress
Randomized Phase 3 Open-label Study of Maribavir vs Investigator-assigned Therapy for Refractory/resistant Cytomegalovirus Infection in Transplant Recipients: Subgroup Analyses of Efficacy by Organ
R. K. Avery¹, E. A. Blumberg², D. Florescu³, N. Kamar⁴, D. Kumar⁵, J. Wu⁶, A. Sundberg⁶
¹Johns Hopkins Hospital, Baltimore, MD, ²University of Pennsylvania, Philadelphia, PA, ³University of Nebraska School of Medicine, Omaha, NE, ⁴Hôpital de Rangueil, Toulouse, France, ⁵University Health Network, Toronto, ON, Canada, ⁶Shire Human Genetic Therapies, Inc., a Takeda company, Lexington, KY
*Purpose: Therapeutic options for refractory, with/without resistance (R/R), CMV infections are limited. We report organ type subgroup analyses from a large multi-center trial that studied…
2021 American Transplant Congress
CD56^dimCD16^bright NK Cells from Kidney Transplant Recipients with Antibody-mediated Rejection Display Increased Proliferation, Type-1 Activation and Cytotoxic Profile
E. Bailly¹, C. Macedo¹, K. Louis¹, B. Ramaswami¹, M. Lucas¹, C. Bentlejewski¹, P. Randhawa¹, A. Zeevi¹, C. Lefaucheur², D. Metes¹
¹Department of Surgery, Thomas E. Starzl Transplantation Institute, Pittsburgh, PA, ²INSERM UMR-S976. Endothelium, Inflammation & Alloreactivity, Université de Paris, Paris, France
*Purpose: CD56dimCD16bright NK cells are highly potent for cytotoxicity through cell-mediated cytotoxicity (CMC), antibody-dependent cell-mediated cytotoxicity (ADCC) and INF-γ production. The contribution of NK cells…
2021 American Transplant Congress
Living Donor Kidney Transplantation Racial Disparities Persist Independent of Social Vulnerability
A. C. Killian¹, M. C. McLeod¹, B. Shelton¹, R. D. Reed¹, P. MacLennan¹, H. Qu¹, B. J. Orandi¹, V. Kumar¹, D. Sawinski², R. M. Cannon¹, D. J. Anderson¹, M. J. Hanaway¹, J. E. Locke¹
¹University of Alabama at Birmingham Hospital, Birmingham, AL, ²Hospital of the University of Pennsylvania, Philadelphia, PA
*Purpose: Living donor kidney transplantation (LDKT) confers a significant survival benefit over deceased donor transplantation. Racial disparities in access to LDKT are well recognized, yet…
2021 American Transplant Congress
Impact of SARS-CoV 2 Infection on Graft Function in Kidney Transplant Recipients: An Academic Single Center Experience
S. Nahi, A. Shetty, S. Tanna, J. Leventhal
Northwestern University, Chicago, IL
*Purpose: Kidney transplant recipients are a unique cohort in regard to SARS-CoV 2 susceptibility and clinical course, owing to their immunosuppressed state and propensity for…
2021 American Transplant Congress
Urinary Exosomal Cystatin C and Lipopolysaccharide Binding Protein as Biomarkers for Monitoring Antibody-mediated Rejection After Kidney Transplantation
M. Kim, S. Lim, S. Shin
Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of
*Purpose: This study aims to discover and validate urinary exosomal biomarkers for antibody-mediated rejection (ABMR) after kidney transplantation.*Methods: A total of 60 urine samples from…
2021 American Transplant Congress
Single Center Experience Comparing Two Clinically Available Donor Derived Cell Free DNA Tests
S. Bunnapradist¹, S. Lee², P. Homkrailas³, G. Danovitch³
¹UCLA, Los Angeles, CA, ²Pharmacy, David Geffen School of Medicine at UCLA, Los Angeles, CA, ³David Geffen School of Medicine at UCLA, Los Angeles, CA
*Purpose: Donor derived cell-free DNA (dd cf-DNA), this new technology allows for non-invasive monitoring of graft function. Two most commonly used assays are Prospera (Natera®,…
2021 American Transplant Congress
Role of Trugraf Testing in Kidney Allografts Previously Biopsied for Dysfunction
Y. A. Qazi¹, W. Mon¹, C. Choi¹, S. Qazi², M. Smogorzewski¹
¹Keck Medical Center at USC, Los Angeles, CA, ²Keck Medical Center at USC, La Canada Flt, CA
*Purpose: TruGraf®, can be used as an alternative to surveillance biopsies for ruling out “silent” subclinical acute rejections in transplant patients with stable graft function.…
2021 American Transplant Congress
A Payer’s Perspective: The Cost of Hemodialysis versus Living Donor Kidney Transplant for Kidney Failure Patients in Nigeria
J. Lang¹, I. James², D. Da Rocha Afodu¹, C. G. Okwuonu³, O. Ekwenna¹
¹University of Toledo College of Medicine and Life Sciences, Toledo, OH, ²Surgical Specialists of Charlotte, Matthews, NC, ³Department of Internal Medicine, Nephrology Unit, Federal Medical Centre, Umuahia, Abia State, Nigeria
*Purpose: To primarily quantify the costs of LDKT and HD in Nigeria from a ‘payer’s perspective’ and secondarily inform future cost-effectiveness studies to guide health…